Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
VISINE is a fixed-dose ophthalmic combination of naphazoline hydrochloride (a decongestant) and pheniramine maleate (an antihistamine) formulated as eye drops. It is indicated for temporary relief of itching and redness due to allergic conjunctivitis and minor eye irritation. The combination works by constricting blood vessels in the eye and blocking histamine receptors to reduce allergic symptoms.
As an established OTC/pharmacy-dispensed product in LOE-approaching phase, the brand team is likely transitioning to line extension and cost optimization strategies rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on VISINE offers stability and deep expertise in OTC channel management, customer relationships, and retail trade dynamics, but limited exposure to clinical development or innovation. Career progression depends on ability to manage mature brands, optimize profitability, and execute line extensions or portfolio transitions as LOE accelerates.
Worked on VISINE at Alcon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.